Streetbeat News

Earnings

BABA

NVDA

RIVN

TSLA

Cryptocurrencies trade mixed as Dogecoin mirrors 2023 bull market patterns, and Bitcoin's potential post-halving correction could target $40K. Rivian rebounds in premarket trading. Analysts predict a pause in US stock rally and discuss potential impacts of a second Trump presidency. International tensions rise with US-China relations and covert operations in Ukraine. Tech sector sees Nvidia's upside potential and Alibaba's optimism, while electric vehicle companies like Tesla and Rivian make headlines. Broadcom nears a strategic sale, and financial deals include Ant Group's acquisition of Credit Suisse's China unit.

Portfolio Pulse from Akanksha Bakshi

February 26, 2024 | 1:46 pm

MOD

Modine (NYSE:MOD) has announced the acquisition of Scott Springfield Manufacturing, a leading air handling unit manufacturer, to enhance its data center technology portfolio and indoor air quality offerings. This strategic move aims to expand Modine's product line and customer base in high-growth markets such as hyperscale data centers and healthcare. The acquisition, valued at approximately $190 million, is expected to close in the first quarter of 2024 and is anticipated to be immediately accretive to earnings. Scott Springfield's fiscal 2023 revenue is expected to exceed $100 million.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:42 pm

CNEY

CN Energy Group has announced its preliminary revenue forecast for Q1 2024, estimating revenues to be between $21.0M and $22.0M.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:42 pm

GILD

Gilead Sciences, Inc. (GILD) announced its participation in CROI 2024, presenting new data from its antiviral research programs, including studies on HIV, COVID-19, and viral hepatitis. Key highlights include findings on Biktarvy and investigational regimens like lenacapavir plus bictegravir, and the impact of Veklury on COVID-19 mortality. The presentations underscore Gilead's commitment to biomedical innovation and addressing global viral disease challenges.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:39 pm

ITRI

Itron's stock price increased following the announcement of its Q4 financial results, which surpassed expectations. Additionally, the company provided Q1 guidance that exceeded analysts' estimates.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:37 pm

ITRI

Itron projects its full-year 2024 revenue to be between $2.275 billion and $2.375 billion, surpassing the estimated $2.292 billion. Additionally, the company anticipates its adjusted EPS to range from $3.40 to $3.80, exceeding the estimated $3.12.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:35 pm

ITRI

Itron projects its Q1 revenue to be between $575M-$585M, surpassing the estimated $541.74M. Additionally, its adjusted EPS is expected to be $0.80-$0.90, exceeding the forecast of $0.58.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:33 pm

PPC

Pilgrim's Pride shares are trading higher following the announcement of their Q4 financial results, which exceeded expectations.

Portfolio Pulse from Luke J Jacobi

February 26, 2024 | 1:33 pm

ITRI

Itron (NASDAQ:ITRI) reported Q4 adjusted EPS of $1.23, surpassing the $0.75 estimate, and sales of $577.17M, exceeding the $570.23M estimate. This represents a 73.24% increase in earnings and a 23.46% increase in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 1:31 pm

KRYS

Krystal Biotech shares are trading higher following the announcement of financial results that exceeded expectations.

Portfolio Pulse from Luke J Jacobi

February 26, 2024 | 1:29 pm